Pathogen-Specific Regulation of Renin-Angiotensin System Genes in Epithelial Cells: A Comparative Study of SARS-CoV-2 Spike Protein N-Terminal Domain Fragment and Bacterial Lipopolysaccharide.

Publication date: Jun 01, 2026

The renin-angiotensin system (RAS) regulates inflammation, tissue homeostasis, and barrier integrity in lung and colon epithelial cells. Beyond classical pathways, non-canonical components including angiotensin-converting enzyme 2 (ACE2), epidermal growth factor receptor (EGFR), insulin-like growth factor 2 receptor (IGF2R) and aminopeptidase N (ANPEP) are implicated in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and bacterial sepsis due to their roles in tissue repair and signaling. Despite their similar inflammatory and coagulopathic features, their impact on RAS-associated non-immune gene expression in epithelial tissues remains unclear. This study investigates the regulation of these targets in lung (BEAS-2B) and colon (CRL-1831) cells following exposure to recombinant SARS-CoV-2 spike protein N-terminal domain fragment (S1-NTD) and Pseudomonas aeruginosa-derived lipopolysaccharide (LPS). Cells were treated with 100 ng/mL of S1-NTD or LPS for 12-72 h. Viability was assessed via XTT assays, and molecular changes were analyzed through qRT-PCR and Western blotting. Both stimuli induced a time and dose-dependent decrease in metabolic activity. ACE2 was significantly downregulated in lung cells, while transient upregulation occurred in colon cells at 24 h. EGFR expression increased in colon cells following LPS exposure but decreased in lung cells after S1-NTD treatment. Both IGF2R and ANPEP were upregulated by S1-NTD in lung cells at 72 h, whereas colon cells showed earlier upregulation at 24-48 h. Our findings reveal that viral and bacterial stimuli elicit distinct, tissue-specific regulatory patterns in RAS-associated pathways. These alterations may contribute to epithelial barrier dysfunction and inflammation, highlighting these proteins as potential targets for managing secondary bacterial infections and inflammatory lung-gut complications in COVID-19.

Open Access PDF

Concepts Keywords
Bacterial ACE2 protein, human
Coronavirus Angiotensin-Converting Enzyme 2
Homeostasis Angiotensin-Converting Enzyme 2
Insulin Cell Line
Severe COVID-19
epithelial barrier dysfunction
Epithelial Cells
ErbB Receptors
ErbB Receptors
Gene Expression Regulation
gene expression regulation
Humans
lipopolysaccharide
Lipopolysaccharides
Lipopolysaccharides
Protein Domains
Pseudomonas aeruginosa
Receptor, IGF Type 2
Receptor, IGF Type 2
Renin-Angiotensin System
renin–angiotensin system
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein
spike protein, SARS-CoV-2

Semantics

Type Source Name
pathway KEGG Renin-angiotensin system
drug DRUGBANK Rasagiline
disease MESH inflammation
disease MESH severe acute respiratory syndrome
disease MESH infections
disease MESH NTD
disease MESH LPS
disease MESH bacterial infections
disease MESH COVID-19
drug DRUGBANK Angiotensin II
disease MESH critically ill
disease MESH cytokine storms
disease MESH sepsis
disease MESH acute respiratory distress syndrome
pathway REACTOME Release
pathway KEGG Virion
drug DRUGBANK Benzylpenicillin
drug DRUGBANK Streptomycin
drug DRUGBANK Sodium lauryl sulfate
disease MESH SDS
disease MESH death
pathway KEGG Viral replication
drug DRUGBANK Isoxaflutole
disease MESH lung injury
drug DRUGBANK Dextrose unspecified form
disease MESH diarrhea
disease MESH malnutrition
disease MESH TAM
drug DRUGBANK Phosphatidyl serine
disease MESH respiratory diseases
disease MESH cholangiocarcinoma
pathway REACTOME EGFR downregulation
drug DRUGBANK Trestolone
disease MESH lung inflammation
disease MESH viral infections
drug DRUGBANK Piroxicam
disease MESH fibrosis
disease MESH Mas
disease MESH dis
drug DRUGBANK Coenzyme M
drug DRUGBANK Guanosine
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH pulmonary fibrosis
disease MESH syndrome
disease MESH coronavirus infections
disease MESH hydatid cyst
pathway REACTOME Apoptosis
disease MESH Park
disease MESH acute lung injury
drug DRUGBANK Naringenin
disease MESH Lam
disease MESH injury
drug DRUGBANK Ursodeoxycholic acid
drug DRUGBANK Diethylstilbestrol
disease MESH des
drug DRUGBANK Bradykinin
disease MESH Neuroinflammation
disease MESH Chronic Obstructive Pulmonary Disease
pathway REACTOME Defensins
drug DRUGBANK Butyric Acid
disease MESH Hypertension
disease MESH Heart Failure

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *